BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36198430)

  • 1. Activation of Stimulator of IFN Genes (STING) Causes Proteinuria and Contributes to Glomerular Diseases.
    Mitrofanova A; Fontanella A; Tolerico M; Mallela S; Molina David J; Zuo Y; Boulina M; Kim JJ; Santos J; Ge M; Sloan A; Issa W; Gurumani M; Pressly J; Ito M; Kretzler M; Eddy S; Nelson R; Merscher S; Burke G; Fornoni A
    J Am Soc Nephrol; 2022 Dec; 33(12):2153-2173. PubMed ID: 36198430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synaptopodin deficiency exacerbates kidney disease in a mouse model of Alport syndrome.
    Ning L; Suleiman HY; Miner JH
    Am J Physiol Renal Physiol; 2021 Jul; 321(1):F12-F25. PubMed ID: 34029143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYDGF attenuates podocyte injury and proteinuria by activating Akt/BAD signal pathway in mice with diabetic kidney disease.
    He M; Li Y; Wang L; Guo B; Mei W; Zhu B; Zhang J; Ding Y; Meng B; Zhang L; Xiang L; Dong J; Liu M; Xiang L; Xiang G
    Diabetologia; 2020 Sep; 63(9):1916-1931. PubMed ID: 32588068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STING deletion alleviates podocyte injury through suppressing inflammation by targeting NLRP3 in diabetic kidney disease.
    Yang X; Chen Z; Luo Z; Yang D; Hao Y; Hu J; Feng J; Zhu Z; Luo Q; Zhang Z; Liang W; Ding G
    Cell Signal; 2023 Sep; 109():110777. PubMed ID: 37329999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour necrosis factor-α drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis.
    Ryu M; Mulay SR; Miosge N; Gross O; Anders HJ
    J Pathol; 2012 Jan; 226(1):120-31. PubMed ID: 21953121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podocyte Injury in Diabetic Kidney Disease in Mouse Models Involves TRPC6-mediated Calpain Activation Impairing Autophagy.
    Salemkour Y; Yildiz D; Dionet L; 't Hart DC; Verheijden KAT; Saito R; Mahtal N; Delbet JD; Letavernier E; Rabant M; Karras A; van der Vlag J; Nijenhuis T; Tharaux PL; Lenoir O
    J Am Soc Nephrol; 2023 Nov; 34(11):1823-1842. PubMed ID: 37678257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Neutralizing IL-11 Antibody Improves Renal Function and Increases Lifespan in a Mouse Model of Alport Syndrome.
    Widjaja AA; Shekeran SG; Adami E; Ting JGW; Tan J; Viswanathan S; Lim SY; Tan PH; Hübner N; Coffman T; Cook SA
    J Am Soc Nephrol; 2022 Apr; 33(4):718-730. PubMed ID: 35140116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxypropyl-β-cyclodextrin protects from kidney disease in experimental Alport syndrome and focal segmental glomerulosclerosis.
    Mitrofanova A; Molina J; Varona Santos J; Guzman J; Morales XA; Ducasa GM; Bryn J; Sloan A; Volosenco I; Kim JJ; Ge M; Mallela SK; Kretzler M; Eddy S; Martini S; Wahl P; Pastori S; Mendez AJ; Burke GW; Merscher S; Fornoni A
    Kidney Int; 2018 Dec; 94(6):1151-1159. PubMed ID: 30301568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sterol-O-acyltransferase-1 has a role in kidney disease associated with diabetes and Alport syndrome.
    Liu X; Ducasa GM; Mallela SK; Kim JJ; Molina J; Mitrofanova A; Wilbon SS; Ge M; Fontanella A; Pedigo C; Santos JV; Nelson RG; Drexler Y; Contreras G; Al-Ali H; Merscher S; Fornoni A
    Kidney Int; 2020 Nov; 98(5):1275-1285. PubMed ID: 32739420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramipril therapy in integrin α1-null, autosomal recessive Alport mice triples lifespan: mechanistic clues from RNA-seq analysis.
    Madison J; Wilhelm K; Meehan DT; Gratton MA; Vosik D; Samuelson G; Ott M; Fascianella J; Nelson N; Cosgrove D
    J Pathol; 2024 Mar; 262(3):296-309. PubMed ID: 38129319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulated expression of integrin α1 in mesangial cells and integrin α3 and vimentin in podocytes of Col4a3-null (Alport) mice.
    Steenhard BM; Vanacore R; Friedman D; Zelenchuk A; Stroganova L; Isom K; St John PL; Hudson BG; Abrahamson DR
    PLoS One; 2012; 7(12):e50745. PubMed ID: 23236390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PFKP Activation Ameliorates Foot Process Fusion in Podocytes in Diabetic Kidney Disease.
    Zhang Z; Liang W; Luo Q; Hu H; Yang K; Hu J; Chen Z; Zhu J; Feng J; Zhu Z; Chi Q; Ding G
    Front Endocrinol (Lausanne); 2021; 12():797025. PubMed ID: 35095764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of disease progression on the podocyte cell cycle in Alport Syndrome.
    Frank CN; Hou X; Petrosyan A; Villani V; Zhao R; Hansen JR; Clair G; Salem F; De Filippo RE; Cravedi P; Lemley KV; Perin L
    Kidney Int; 2022 Jan; 101(1):106-118. PubMed ID: 34562503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA-binding proteins tristetraprolin and human antigen R are novel modulators of podocyte injury in diabetic kidney disease.
    Guo J; Lei M; Cheng F; Liu Y; Zhou M; Zheng W; Zhou Y; Gong R; Liu Z
    Cell Death Dis; 2020 Jun; 11(6):413. PubMed ID: 32487989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Podocyte-specific Nlrp3 inflammasome activation promotes diabetic kidney disease.
    Shahzad K; Fatima S; Khawaja H; Elwakiel A; Gadi I; Ambreen S; Zimmermann S; Mertens PR; Biemann R; Isermann B
    Kidney Int; 2022 Oct; 102(4):766-779. PubMed ID: 35779608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Albumin contributes to kidney disease progression in Alport syndrome.
    Jarad G; Knutsen RH; Mecham RP; Miner JH
    Am J Physiol Renal Physiol; 2016 Jul; 311(1):F120-30. PubMed ID: 27147675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.
    Dufek B; Meehan DT; Delimont D; Cheung L; Gratton MA; Phillips G; Song W; Liu S; Cosgrove D
    Kidney Int; 2016 Aug; 90(2):300-310. PubMed ID: 27165837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discoidin domain receptor 1 activation links extracellular matrix to podocyte lipotoxicity in Alport syndrome.
    Kim JJ; David JM; Wilbon SS; Santos JV; Patel DM; Ahmad A; Mitrofanova A; Liu X; Mallela SK; Ducasa GM; Ge M; Sloan AJ; Al-Ali H; Boulina M; Mendez AJ; Contreras GN; Prunotto M; Sohail A; Fridman R; Miner JH; Merscher S; Fornoni A
    EBioMedicine; 2021 Jan; 63():103162. PubMed ID: 33340991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated podocyte detachment and progressive podocyte loss from glomeruli with age in Alport Syndrome.
    Ding F; Wickman L; Wang SQ; Zhang Y; Wang F; Afshinnia F; Hodgin J; Ding J; Wiggins RC
    Kidney Int; 2017 Dec; 92(6):1515-1525. PubMed ID: 28754557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomechanical strain causes maladaptive gene regulation, contributing to Alport glomerular disease.
    Meehan DT; Delimont D; Cheung L; Zallocchi M; Sansom SC; Holzclaw JD; Rao V; Cosgrove D
    Kidney Int; 2009 Nov; 76(9):968-76. PubMed ID: 19710627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.